Pivotal Therapeutics says main goals met in Omega-3 therapy trial; results to...
Pivotal Therapeutics (OTCQX:PVTTF) (CNSX:PVO), a pharma company focused on Omega-3 therapies for cardiovascular disease (CVD), says that it has met the main goals of a trial for its prescription-only...
View ArticlePivotal Therapeutic’s Omega-3 Vascazen product: the way to the heart
For years, we have been told that Omega 3s can help boost health. But some of us may need more than a little fish to make the difference. Pivotal Therapeutics (OTCQX:PVTTF) (CNSX:PVO) has an U.S....
View ArticlePivotal Therapeutics narrows losses on first sales of Vascazen as product...
Pivotal Therapeutics (OTCQX:PVTTF) (CNSX:PVO), a pharmaceutical company focused on Omega-3 therapies for cardiovascular disease, has unveiled its year-end results, narrowing its loss from a year...
View ArticlePivotal Therapeutics to present "top line" results from Vascazan clinical...
Pivotal Therapeutics (OTCQX:PVTTF) (CNSX:PVO), a pharmaceutical company focused on Omega-3 therapies for cardiovascular disease, says it will be presenting its "top line" results from a recent...
View ArticlePivotal Therapeutics' chief scientific officer snags Diamond Jubilee medal...
Pivotal Therapeutics (OTCQX:PVTTF) (CNSX:PVO) has said that its founder, chairman and chief scientific officer, Dr. George Jackowski, was awarded the Queen Elizabeth II Diamond Jubilee Medal earlier...
View ArticlePivotal Therapeutics says Vascazen product can correct Omega-3 deficiency in...
Pivotal Therapeutics (OTCQX:PVTTF) (CNSX:PVO), a specialty pharmaceutical company focused on Omega-3 therapies for cardiovascular disease (CVD), revealed today results from its Vascazen "Reveal"...
View ArticleOmthera acquisition highlights upside potential of Pivotal Therapeutics
A recent deal in the pharmaceutical sector has shone a light on the fact that Pivotal Therapeutics (CNSX:PVO) (OTCQX:PVTTF) is undervalued, with investors seeing potential for the stock to be valued at...
View ArticleOmthera acquisition highlights upside potential of Pivotal Therapeutics
A recent deal in the pharmaceutical sector has shone a light on the fact that Pivotal Therapeutics (CNSX:PVO) (OTCQX:PVTTF) is undervalued, with investors seeing potential for the stock to be valued at...
View ArticlePivotal Therapeutics brings Vascazen product to light in New York at One2One...
Our next Proactive Investors One2One Forum in New York will take investors through the exciting world of Omega-3 therapies with Pivotal Therapeutics (CNSX:PVO) (OTCQX:PVTTF), which is advancing the...
View ArticlePivotal Therapeutics says Q2 sales grow 27% as Vascazen impresses cardiologists
Pivotal Therapeutics (OTCQX: PVTTF) (CNSX: PVO), a specialty pharmaceutical company focused on Omega-3 therapies for cardiovascular disease (CVD), saw its sales jump 27 per cent in the second quarter...
View ArticlePivotal Therapeutics to raise $5 mln through debt financing, $2.7 mln equity...
Pivotal Therapeutics (OTCQX:PVTTF) (CNSX:PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD), says it has agreed to a C$5.0 million debt...
View ArticlePivotal Therapeutics appoints cardiology veteran to its board of directors
Pivotal Therapeutics (OTCQX:PVTTF) (CNSX:PVO) has appointed Dr. John P. Nicholson Jr., a cardiologist and clinical associate professor of medicine at Cornell University, to the company's board of...
View Article
